Thank You for Meeting Us

We enjoyed meeting you at the Association for Research in Vision and Ophthalmology meeting

Cognition Therapeutics is planning to conduct a clinical trial in patients with dry age-related macular degeneration (dry AMD). The study will utilize Cognition’s proprietary lead product candidate, CT1812, an orally delivered, small molecule designed to cross the blood-retina barrier and bind selectively to the sigma-2 (σ-2) receptor complex, a key regulator of cellular damage and stress response.

The σ-2 complex is expressed in the retina in several cell types including the retinal pigment epithelial cells (RPE), photoreceptors and retinal ganglion cells. We believe that a σ-2 receptor antagonist, such as CT1812, may help to regulate the damage-response processes related to these cells that are impaired in dry AMD.

Download
our Vcard

Ongoing Clinical Programs

Indication

Preclinical

Phase 1

Phase 2

Phase 3

SHINE (COG0201) Study

SEQUEL (COG0202) Study

COG0203 in Collaboration with the ACTC

Including Parkinson's disease and DLB

* Subject to discussion with FDA, this clinical development program will begin with a Phase 2 study supported by the Phase 1 AD studies

Novel Approach

The σ-2 receptor is expressed by multiple cell types, including neuronal synapses in the brain and RPE, RGC and photoreceptors in the eye. The σ-2 complex is comprised of transmembrane protein 97 (TMEM97), a four-domain transmembrane protein that forms a complex with progesterone receptor membrane component 1 (PGRMC1).

Human genetic and internal proteomic pathway analyses obtained through our AD trials provides evidence of a relationship between the σ-2 complex and dry AMD.

We believe that targeting the σ-2 complex represents a mechanism that is functionally distinct from other current approaches in clinical development for the treatment of dry AMD.

Presentations and Publications

ARVO 2022

We presented preclinical results at ARVO 2022 showing that Aβ oligomer- and oxidative stress-induced deficits in RPE-mediated photoreceptor outer segment (POS) phagocytosis may be rescued by a σ-2 modulator.

This poster is embargoed until May 3, 2022.

Click on the poster below to view and download the PDFs.

Publications

Cognition Therapeutics has several publications on the σ-2 receptor, its role in neurological disorders such as Alzheimer’s disease and results of earlier studies. These may be found on our Publications webpage.

In dry AMD, several published papers support the approach that we are pursuing and are listed below.

click to open and download

Contact Cognition's Clinical Operations Team

Scroll to Top

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

Thank you

Someone from the Cognition Therapeutics team
will be in touch with you soon.